Aspire Biopharma files provisional patent application for Meclizine formulation

Aspire Biopharma (ASBP) Holdings announced the filing of a provisional patent application with the U.S. Patent and Trademark Office for its proprietary sublingual powder formulation of Meclizine. The application, titled “A Sublingual Powder Formulation of Meclizine and Methods of Use Thereof,” represents a significant leap in antiemetic therapy. By introducing the first-ever sublingual powder delivery system for Meclizine, Aspire aims to eliminate the traditional “waiting period” associated with oral tablets, providing near-instant relief for nausea, vomiting, and vertigo.